Logo

Agendia

Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe

Agendia will receive co-exclusive rights to distribute Inivata's RaDaR assay for minimal residual disease and relapse detection in Europe and North America.

Agendia FLEX Registry Powers Genomics Research on Underrepresented Breast Cancer Patients
Premium

FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.

Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures

The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.

Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests

Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.

PathoNext to Offer Agendia's Breast Cancer Recurrence Assays in Germany

PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.

Aug 26, 2020

Agendia's MammaPrint Breast Cancer Risk Test Cost-Effective in Multi-Country Analysis

Jul 2, 2020

Agendia Settles Allegations of Medicare Fraud for $8.25M

Jun 12, 2020

New Data Support Role of Agendia BluePrint Test in Refining Breast Cancer Subtypes
Premium

May 21, 2019

Agendia, Imegen Ink Distribution Deal for Breast Cancer Tests in Spain, Portugal

Dec 19, 2018

Breast Cancer Molecular Tests Included in Recommendations by UK's NICE

Dec 10, 2018

SABCS 2018 Features Molecular Diagnostics Research

Nov 16, 2018

Agendia Breast Cancer Tests Show Promise for Improved Therapy Prediction
Premium

Oct 10, 2018

NCCN Update on Breast Cancer Genetic Testing Guidelines Marks Oncotype DX as 'Preferred' Test

Sep 18, 2018

Agendia Partners With GeneCast to Launch Tests in China

Aug 24, 2018

In Brief This Week: MolecularMD, Agendia, Promega, NRGene, More

Jul 25, 2018

Agendia Secures $35M Investment

May 24, 2018

Agendia Inks Southeast Asian Marketing Deal for Breast Cancer Tests

May 15, 2018

Agendia Breast Cancer Tests Adopted by French Hospital Group

May 1, 2018

Aetna, Cigna, UnitedHealthcare to Cover Agendia's MammaPrint

Apr 5, 2018

Agendia Moving to Decentralized Testing Model in Europe, Exploring Options for Asia Expansion
Premium

Mar 21, 2018

Agendia NGS MammaPrint BluePrint Kit Receives CE Mark

Feb 7, 2018

UK's NICE Finalizing Updated Breast Cancer Test Guidance Following Stakeholder Comments
Premium

Dec 19, 2017

Agendia Selects Bluebee as Data Processing Partner for MammaPrint, BluePrint IVD Kit

Dec 7, 2017

University Hospitals Leuven Joins Validation Effort for Agendia MammaPrint, BluePrint IVD Kit

Dec 5, 2017

Institut Curie Joins Co-Validation Study for Agendia's MammaPrint, BluePrint Breast Cancer Kit

Breaking News
The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.